Rodrigo Sánchez-Bayona
@Rodrosb
Followers
5K
Following
6K
Media
257
Statuses
3K
MD, PhD. Oncólogo | Unidad de Cáncer de Mama y Ginecológico Hospital 12 de Octubre (Spain) | ESMO Young Oncologists Committee Chair
Joined May 2012
✨ A bit more than a week ago, we had the incredible #ESMO25 meeting, celebrating the 50th anniversary of @myESMO ! 🎉 @Rodrosb @LizzySmyth1 @amanda_psyrri @DrAngelaLamarca @DrChoueiri @MyriamChalabi @Prof_Nadia_H @CarlosGome39118 Brigette B.Y. Ma
0
5
26
That’s a wrap on #ESMO25 A truly meaningful meeting: joining @myESMO Young Oncologists Committee & Leadership Programme, and engaging with the broader work of this impactful society Grateful for the discussions, connections & remarkable science throughout the week! @OncoAlert
0
3
9
The YOC roundtable session was a blast!
⭐️The future of oncology is bright. One of the greatest privileges: educating the next generation. Grateful to lead @myESMO ESMO-ESCAT workshop with brilliant young oncologists. #ESMO #Oncology I love their curiosity, drive, and the best was the brilliant Q and A session
0
7
40
#ESMO25 is coming to an end, and as YOC Chair I couldn’t be more proud of this bunch of friends who have devotedly and tirelessly delivered one of the best YO tracks ever! @myESMO #ESMOAmbassadors
1
8
31
🌍✨ A night to remember at the #ESMO2025 Presidential Dinner — uniting oncologists from every corner of the world in the spirit of collaboration, innovation, and hope. Here's to pushing boundaries together and shaping the future of cancer care. 💪🧬 @myESMO @ASCO @LaStatale
0
8
41
Anti-TROP2 ADCs in 1L mTNBC. Some key differences between ASCENT03 and TROPION02: 🧐Cross-over to SG allowed, and doublet chemo (carbo gem) in ASCENT03 in 50% pts monoCht taxane was the comparator for more than 2/3 of patients in TROPION02 @myESMO #ESMOAmbassadors #ESMO25
0
1
6
According to this, and thinking of sequencing treatment options: would you consider TDXd for patients with a previous everolimus-related ILD? @PTarantinoMD @PabloMando @matteolambe
1
3
4
Have a look at the rate of ILD/pneumonitis with everolimus plus ET, approx 15-20% of patients.
2
0
3
The ph3 evERA trial provides the first prospective randomized data of the efficacy of everolimus plus ET in the post-CDK4/6inh setting in MBC. For ESR1m mPFS 5,5 months for EVE plus SOC ET vs 10 months for EVE plus Giredestrant @myESMO #ESMOAmbassadors
1
2
6
Spotlight results from the RIBOLARIS Trial in HR+/HER2- EBC: more than half of patients achieving a molecular down staging in ROR after 6 months of NEO ribociclib plus NSAI (meaning these patients could spare chemotherapy) @myESMO #ESMOAmbassadors
5
3
16
The 5 pillars of modern Oncology, @myESMO President in the Opening Ceremony of #ESMO25 Congress #ESMOAmbassadors
1
3
21
3️⃣ AI Joins the Tumor Board 🤖Expect real-world evidence on how Artificial Intelligence is predicting treatment response from pathology images. This isn't sci-fi—it's the future of personalizing therapy, and the first major results are coming.
0
0
2
2️⃣ HER2 and beyond 🎯: The New Targets. The spotlight is expanding! Look for updates on exciting new targets like HER3 and FRα. We'll see more data on antibody-drug conjugates (ADCs) that are reshaping treatment for a wider range of patients.
1
0
2
1️⃣ The "Where & When" of Treatment 🗓️ Get ready for data on treatment duration. When can we safely stop therapies for some patients? ESMO 2025 will bring answers on de-escalation to maintain quality of life without sacrificing efficacy.
1
0
2
#ESMO25 is almost here! #ESMOAmbassadors 3 areas of interest that will be revisited during this congress, here we go 👇🏻
1
0
2
El momento exacto en que María Corina Machado se entera del premio Nobel: "Dios mío, solo soy una persona"
63
591
2K
#ESMO25: Discover the latest #CancerResearch insights brought to you by #ESMOAmbassadors and join the conversation in #oncology. 🔗 https://t.co/YZZN0sQyBS
4
16
47
En el marco del Día Mundial de la Investigación contra el Cáncer, Economist Impact celebró hasta última hora de ayer, una jornada entorno a su trabajo de investigación "Avances en la atención del cáncer de mama en Europa: hoja de ruta hacia un enfoque centrado en las mujeres".
0
2
4
🎂 El Centro de Oncología Experimental del #Hospital12deOctubre cumple dos años. 🔬 Más de 100 investigadores y 156 estudios activos centrados en los tumores de mayor impacto. 👉 Referente nacional e internacional en cáncer. + info: https://t.co/LZBzo0BIwj
#somosdel12
1
25
57